Shares of Novo Nordisk A/S plunged after the company surprised investors with a forecast pointing to a sharp drop in sales, underscoring the growing intensity of price competition in the obesity drug market.

U.S.-based coffeehouse chain Starbucks has reported a sales decline for the third consecutive quarter, as detailed in its financial results statement released on Wednesday.